(Q30329791)

18 June 2017

1 reference

title

Vaccine development against HIV-1: current perspectives and future directions. (English)

1 reference

18 June 2017

Rebecca L Edgeworth

1

1 reference

18 June 2017

Juan Homero San

2

1 reference

18 June 2017

Jason A Rosenzweig

3

1 reference

18 June 2017

Nang L Nguyen

4

1 reference

18 June 2017

Jean D Boyer

5

1 reference

18 June 2017

Kenneth E Ugen

6

1 reference

18 June 2017

publication date

1 January 2002

1 reference

18 June 2017

1 reference

18 June 2017

volume

25

1 reference

18 June 2017

issue

1

1 reference

18 June 2017

page(s)

53-74

1 reference

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

18 June 2017

cites work

1 reference

12 December 2020

DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.

1 reference

12 December 2020

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection

1 reference

12 December 2020

IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine

1 reference

12 December 2020

Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys

1 reference

12 December 2020

FIV infection of the domestic cat: an animal model for AIDS.

1 reference

12 December 2020

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

1 reference

12 December 2020

Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment

1 reference

12 December 2020

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group

1 reference

12 December 2020

Chimeric SHIV that causes CD4+ T cell loss and AIDS in rhesus macaques

1 reference

12 December 2020

Human trials of experimental AIDS vaccines

1 reference

12 December 2020

Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes

1 reference

12 December 2020

Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1

1 reference

12 December 2020

The simian immunodeficiency viruses

1 reference

12 December 2020

Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1.

1 reference

12 December 2020

Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus

1 reference

12 December 2020

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group

1 reference

12 December 2020

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

1 reference

12 December 2020

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

1 reference

12 December 2020

DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees

1 reference

12 December 2020

Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats

1 reference

12 December 2020

In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen

1 reference

12 December 2020

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

1 reference

12 December 2020

HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients

1 reference

12 December 2020

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

12 December 2020

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles

1 reference

12 December 2020

Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice

1 reference

12 December 2020

Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection

1 reference

12 December 2020

Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein

1 reference

12 December 2020

Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy

1 reference

12 December 2020

Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial

1 reference

12 December 2020

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS

1 reference

12 December 2020

Identification of highly attenuated mutants of simian immunodeficiency virus

1 reference

12 December 2020

Delayed progression of murine AIDS in C57BL/6 mice pre-immunized with a highly antigenic 10-mer peptide encoded by the murine AIDS defective virus gag p12 gene

1 reference

12 December 2020

Infection of baboons with simian/human immunodeficiency viruses

1 reference

12 December 2020

Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

1 reference

12 December 2020

Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV

1 reference

12 December 2020

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.

1 reference

12 December 2020

Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes

1 reference

12 December 2020

Toward an understanding of the correlates of protective immunity to HIV infection

1 reference

12 December 2020

Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope

1 reference

12 December 2020

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen

1 reference

12 December 2020

Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected i

1 reference

12 December 2020

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.

1 reference

12 December 2020

A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation

1 reference

12 December 2020

AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free

1 reference

12 December 2020

Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines

1 reference

12 December 2020

Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines

1 reference

12 December 2020

Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

1 reference

12 December 2020

Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys

1 reference

12 December 2020

Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response

1 reference

12 December 2020

Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies

1 reference

12 December 2020

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

1 reference

12 December 2020

Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

1 reference

12 December 2020

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

1 reference

12 December 2020

Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins

1 reference

12 December 2020

Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice

1 reference

12 December 2020

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

1 reference

12 December 2020

Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial.

1 reference

12 December 2020

Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge

1 reference

12 December 2020

DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses

1 reference

12 December 2020

Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination

1 reference

12 December 2020

Simian immunodeficiency virus DNA vaccine trial in macaques.

1 reference

12 December 2020

Infection of baboons with a simian immunodeficiency virus/HIV-1 chimeric virus constructed with an HIV-1 Thai subtype E envelope

1 reference

12 December 2020

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

12 December 2020

DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies

1 reference

12 December 2020

B7 co-stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination

1 reference

12 December 2020

Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus

1 reference

12 December 2020

Genetic diversity of simian immunodeficiency viruses from West African green monkeys: evidence of multiple genotypes within populations from the same geographical locale.

1 reference

12 December 2020

Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women

1 reference

12 December 2020

Protection by live, attenuated simian immunodeficiency virus against heterologous challenge.

1 reference

12 December 2020

Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees.

1 reference

12 December 2020

Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.

1 reference

12 December 2020

In vivo protective anti-HIV immune responses in non-human primates through DNA immunization.

1 reference

12 December 2020

Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes.

1 reference

12 December 2020

Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1

1 reference

12 December 2020

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls

1 reference

12 December 2020

Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1.

1 reference

12 December 2020

Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

1 reference

12 December 2020

Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen

1 reference

12 December 2020

Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge

1 reference

12 December 2020

Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids.

1 reference

12 December 2020

Humoral and cellular immune responses to HIV-1 Nef in mice DNA-immunised with non-replicating or self-replicating expression vectors

1 reference

12 December 2020

The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants

1 reference

12 December 2020

Long-term protection of macaques against high-dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins

1 reference

12 December 2020

HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody

1 reference

12 December 2020

Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants

1 reference

12 December 2020

Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site

1 reference

12 December 2020

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

1 reference

12 December 2020

Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals

1 reference

12 December 2020

Enhancement after feline immunodeficiency virus vaccination

1 reference

12 December 2020

Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

1 reference

12 December 2020

Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection

1 reference

12 December 2020

Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.

1 reference

12 December 2020

Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees.

1 reference

12 December 2020

Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine

1 reference

12 December 2020

Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques

1 reference

12 December 2020

Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.

1 reference

12 December 2020

Comparison of the immune response to recombinant gp120 in humans and chimpanzees

1 reference

12 December 2020

Antibody neutralization of HIV-1 and the potential for vaccine design.

1 reference

12 December 2020

HIV-1 DNA vaccines and chemokines.

1 reference

12 December 2020

A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection

1 reference

12 December 2020

Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus

1 reference

12 December 2020

Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis

1 reference

12 December 2020

Identification of a novel posttranscriptional regulatory element by using a rev- and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap

1 reference

12 December 2020

Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence

1 reference

12 December 2020

Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218)

1 reference

12 December 2020

Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies

1 reference

12 December 2020

Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

1 reference

12 December 2020

Development of peptide vaccines inducing production of neutralizing antibodies against HIV-1 viruses in HLA-DQ6 mice

1 reference

12 December 2020

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

12 December 2020

Cationic microparticles: A potent delivery system for DNA vaccines

1 reference

12 December 2020

Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development

1 reference

12 December 2020

Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III.

1 reference

12 December 2020

Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials

1 reference

12 December 2020

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

1 reference

12 December 2020

DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans

1 reference

12 December 2020

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1385/IR:25:1:53

1 reference

Dimensions Publication ID

18 June 2017

1028525565

0 references

1 reference